Dorzolamide et timolol : interactions médicamenteuses

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (notice Alogliptine et metformine, Mise en garde encadrée)

CONTRAINDICATIONS Atenolol and chlorthalidone is contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (See WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs. (notice Aténolol et chlortalidone, Contre-indications)

Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (notice Bénazépril et hydrochlorothiazide, Contre-indications)

CONTRAINDICATIONS Bisoprolol fumarate and hydrochlorothiazide tablets are contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS ), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. (notice Bisoprolol et hydrochlorothiazide, Contre-indications)

CONTRAINDICATIONS Candesartan cilexetil and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs. (notice Candésartan et hydrochlorothiazide, Contre-indications)

• In patients who have demonstrated allergic-type reactions to sulfonamides [ see Warnings and Precautions (5.7) ]. (notice Célécoxib, Contre-indications)

Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed. (notice Chloroprocaïne, Précautions)

Hypersensitivity to this product or to other sulfonamide-derived drugs. (notice Chlorothiazide, Contre-indications)

THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (notice Chlortalidone, Contre-indications)

Cidofovir injection is contraindicated in patients with a history of clinically severe hypersensitivity to probenecid or other sulfa-containing medications. (notice Cidofovir, Contre-indications)

• Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (notice Dapagliflozine et metformine, Mise en garde encadrée)

KEVEYIS is contraindicated in the following circumstances: Hypersensitivity to dichlorphenamide or other sulfonamides [see Warnings and Precautions (5.1) ] Concomitant use of KEVEYIS and high dose aspirin [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ] Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS [see… (notice Diclofénamide, Contre-indications)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin-containing products, including JALYN. (notice Dutastéride et tamsulosine, Mises en garde et précautions)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (notice Empagliflozine et metformine, Mise en garde encadrée)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (notice Énalapril et hydrochlorothiazide, Contre-indications)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (notice Flécaïnide, Mise en garde encadrée)

Fosinopril sodium and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to fosinopril, to any other ACE inhibitor, to hydrochlorothiazide, or other sulfonamide-derived drugs, or any other ingredient or component in the formulation. (notice Fosinopril et hydrochlorothiazide, Contre-indications)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g. , acute congestive heart failure), excessive alcohol intake, hepatic… (notice Glibenclamide et metformine, Mise en garde encadrée)

• Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets.Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. (notice Glimépiride, Contre-indications)

• Hypersensitivity to sulfonamide derivatives. ▪ Known hypersensitivity to glipizide or any of the product's ingredients ( 4 ). ▪ Hypersensitivity to sulfonamide derivatives ( 4 ). (notice Glipizide, Contre-indications)

In patients with hypersensitivity to sulfonamide-derived drugs. (notice Hydrochlorothiazide, Contre-indications)

Known hypersensitivity to indapamide or to other sulfonamide-derived drugs. (notice Indapamide, Contre-indications)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (notice Irbésartan et hydrochlorothiazide, Contre-indications)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Dorzolamide et timolol, Mises en garde et précautions)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Dorzolamide et timolol, Mises en garde et précautions)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (notice Linagliptine et metformine, Mise en garde encadrée)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Dorzolamide et timolol, Mises en garde et précautions)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (notice Lisinopril et hydrochlorothiazide, Contre-indications)

Patients receiving antibiotics and sulfonamides should generally not be treated with ganglion blockers. (notice Mécamylamine, Contre-indications)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic… (notice Metformine, Mise en garde encadrée)

In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (notice Métirosine, Mises en garde)

Anuria Hypersensitivity to metoprolol tartrate or hydrochlorothiazide or to other sulfonamide- derived drugs. (notice Métoprolol et hydrochlorothiazide, Contre-indications)

Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent tachycardia and increased myocardial workload. (notice Minoxidil, Mise en garde encadrée)

Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (notice Nébivolol, Interactions médicamenteuses)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (notice Olmésartan, amlodipine et hydrochlorothiazide, Contre-indications)

Avoid use of phentermine and topiramate extended-release capsules with other carbonic anhydrase inhibitors. (notice Phentermine et topiramate, Mises en garde et précautions)

Use in patients with known history of an allergic reaction to sulfonamide derivatives. (notice Pioglitazone et glimépiride, Contre-indications)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (notice Pioglitazone et metformine, Mise en garde encadrée)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Dorzolamide et timolol, Mises en garde et précautions)

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (notice Protamine, Mise en garde encadrée)

Because of the hydrochlorothiazide components, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (notice Quinapril et hydrochlorothiazide, Contre-indications)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (notice Répaglinide, Interactions médicamenteuses)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (notice Rivastigmine, Interactions médicamenteuses)

• Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure ), excessive alcohol intake, hepatic… (notice Saxagliptine et metformine, Mise en garde encadrée)

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic… (notice Sitagliptine et metformine, Mise en garde encadrée)

CONTRAINDICATIONS Spironolactone and hydrochlorothiazide tablets are contraindicated in patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, hypercalcemia, hyperkalemia, Addison's disease, and in patients who are allergic to thiazide diuretics or to other sulfonamide-derived drugs. (notice Spironolactone et hydrochlorothiazide, Contre-indications)

If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering tamsulosin hydrochloride capsules. (notice Tamsulosine, Mises en garde et précautions)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Dorzolamide et timolol, Mises en garde et précautions)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (notice Dorzolamide et timolol, Mises en garde et précautions)

Kidney stones: avoid use with other carbonic anhydrase inhibitors, drugs causing metabolic acidosis, or in patients on a ketogenic diet ( 5.13 ) (notice Topiramate, Mises en garde et précautions)

…Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (notice Tranylcypromine, Interactions médicamenteuses)

Hypersensitivity Hypersensitivity to either drug in the preparation or to other sulfonamide-derived drugs is a contraindication. (notice Triamtérène et hydrochlorothiazide, Contre-indications)

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. (notice Valsartan et hydrochlorothiazide, Contre-indications)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable. (notice Acétazolamide, Interactions médicamenteuses)

Intervention: During concomitant use of mefenamic acid and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Acide méfénamique, Interactions médicamenteuses)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (notice Dorzolamide et timolol, Mises en garde et précautions)

Use with caution in patients with a known hypersensitivity to sulfonamides ( 5.8 ) (notice Almotriptan, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Beta-blockers may decrease effectiveness. (notice Arformotérol, Interactions médicamenteuses)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (notice Dorzolamide et timolol, Mises en garde et précautions)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (notice Bromocriptine, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Budésonide et formotérol, Interactions médicamenteuses)

Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (notice Bupivacaïne, Mises en garde et précautions)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (notice Dorzolamide et timolol, Mises en garde et précautions)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (notice Carvédilol, Interactions médicamenteuses)

DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (notice Céviméline, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Abrupt discontinuation of QLONILIK can cause rebound hypertension with elevated plasma catecholamines, especially with higher doses or concomitant beta-blocker use. (notice Clonidine, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Intervention: During concomitant use of ZIPSOR and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Diclofénac, Interactions médicamenteuses)

• During concomitant use of diclofenac sodium/misoprostol and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Diclofénac et misoprostol, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (notice Dihydroergotamine, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (notice Dofétilide, Interactions médicamenteuses)

Give a low dose of beta-blockers initially, and increase only after ECG verification of good tolerability [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (notice Dronédarone, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (notice Ergotamine et caféine, Interactions médicamenteuses)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Intervention: Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs. (notice Fénoprofène, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Intervention: During concomitant use of flurbiprofen and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Flurbiprofène, Interactions médicamenteuses)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (notice Dorzolamide et timolol, Interactions médicamenteuses)

• Beta-blockers may decrease effectiveness. (notice Formotérol, Interactions médicamenteuses)

Fosamprenavir calcium should be used with caution in patients with a known sulfonamide allergy. (notice Fosamprénavir, Mises en garde et précautions)

…voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen,… (notice Fosphénytoïne, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (notice Glucagon, Interactions médicamenteuses)

During concomitant use of hydrocodone bitartrate and ibuprofen tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Hydrocodone et ibuprofène, Interactions médicamenteuses)

Intervention: During concomitant use of CALDOLOR and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Ibuprofène, Interactions médicamenteuses)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Ibuprofène et famotidine, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Intervention: During concomitant use of INDOCIN and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Indométacine, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects. (notice Isoflurane, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Beta Blockers Nadolol Monitor for adverse reactions. (notice Itraconazole, Interactions médicamenteuses)

The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (notice Ivabradine, Interactions médicamenteuses)

Antivirals indinavir, maraviroc, saquinavir Beta Blockers nadolol Calcium Channel Blockers felodipine, nisoldipine other dihydropyridines, verapamil Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. (notice Kétoconazole, Interactions médicamenteuses)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (notice Lacosamide, Mises en garde et précautions)

Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (notice Lanréotide, Interactions médicamenteuses)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (notice Lédipasvir et sofosbuvir, Mises en garde et précautions)

In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution. (notice Lévosalbutamol, Interactions médicamenteuses)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (notice Losartan et hydrochlorothiazide, Mises en garde et précautions)

There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (notice Méfloquine, Interactions médicamenteuses)

Intervention: During concomitant use of QAMZOVA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Méloxicam, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (notice Mépivacaïne, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (notice Méthylergométrine, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (notice Motixafortide, Mises en garde et précautions)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Intervention: During concomitant use of Naproxen Suspension and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Naproxène, Interactions médicamenteuses)

Intervention : • During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Naproxène et ésoméprazole, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (notice Octréotide, Mises en garde et précautions)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (notice Olmésartan et hydrochlorothiazide, Mises en garde et précautions)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

Intervention: During concomitant use of OXAPROZIN CAPSULES and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Oxaprozine, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Intervention: • During concomitant use of COMBOGESIC and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Paracétamol et ibuprofène, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (notice Pasiréotide, Mises en garde et précautions)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (notice Phénelzine, Mises en garde)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

…voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen,… (notice Phénytoïne, Interactions médicamenteuses)

Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (notice Pilocarpine, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Intervention: • During concomitant use of Piroxicam Capsules and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (notice Piroxicam, Interactions médicamenteuses)

Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (notice Ponésimod, Mises en garde et précautions)

Hypotension may develop in patients given prazosin hydrochloride capsules who are also receiving a beta-blocker such as propranolol. (notice Prazosine, Mises en garde)

Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. (notice Dorzolamide et timolol, Mises en garde et précautions)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (notice Probénécide, Interactions médicamenteuses)

Probenecid produces an insignificant increase in free sulfonamide plasma concentrations but a significant increase in total sulfonamide plasma levels. (notice Probénécide et colchicine, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (notice Pyridostigmine, Mises en garde et précautions)

However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim- sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. (notice Pyriméthamine, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Decrease exposure Beta-blockers Metoprolol Decrease exposure Propranolol Decrease exposure Benzodiazepines Diazepam , Administered with rifampin 1200 mg daily Decrease exposure Benzodiazepine-related drugs Zopiclone Decrease AUC by 82% Zolpidem Decrease AUC by 73% Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as… (notice Rifampicine, Interactions médicamenteuses)

…Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (notice Rifapentine, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (notice Ropivacaïne, Mises en garde et précautions)

Beta-blockers: Use with caution. (notice Salbutamol, Interactions médicamenteuses)

• Beta-blockers: Use with caution. (notice Salmétérol, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (notice Sofosbuvir et velpatasvir, Mises en garde et précautions)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (notice Sulfaméthoxazole et triméthoprime, Interactions médicamenteuses)

High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). (notice Dorzolamide et timolol, Interactions médicamenteuses)

Intervention: During concomitant use of sumatriptan and naproxen sodium tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained [see Warnings and Precautions (5.8)] . (notice Sumatriptan et naproxène, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (notice Telmisartan et hydrochlorothiazide, Mises en garde et précautions)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (notice Dorzolamide et timolol, Interactions médicamenteuses)

In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (notice Terbutaline, Précautions)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (notice Dorzolamide et timolol, Mises en garde et précautions)

Antihypertensives Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects. (notice Trinitrine, Interactions médicamenteuses)

• Beta-blockers: Use with caution. (notice Uméclidinium et vilantérol, Interactions médicamenteuses)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (notice Dorzolamide et timolol, Interactions médicamenteuses)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (notice Dorzolamide et timolol, Mises en garde et précautions)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol. (notice Dorzolamide et timolol, Interactions médicamenteuses)

Zileuton increases propranolol levels and beta-blocker activity. (notice Zileuton, Interactions médicamenteuses)

• Concomitant use of ZONISADE with any other carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation ( 7.2 ). (notice Zonisamide, Interactions médicamenteuses)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (notice Adénosine, Interactions médicamenteuses)

Other Antibacterials Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. (notice Amoxicilline, Interactions médicamenteuses)

Bacteriostatic Antibiotics : Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins. (notice Ampicilline, Interactions médicamenteuses)

As with other beta-blockers, when discontinuation of TENORMIN is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. (notice Aténolol, Mises en garde)

Drug Interactions BISOPROLOL FUMARATE should not be combined with other beta-blocking agents. (notice Bisoprolol, Interactions médicamenteuses)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (notice Bleu de méthylène, Mises en garde et précautions)

Allergy to Sulfonamides Patients allergic to sulfonamides may show hypersensitivity to bumetanide. (notice Bumétanide, Mises en garde)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (notice Carbamazépine, Interactions médicamenteuses)

Effects on the absorption of other beta-blockers have not been determined. (notice Colestipol, Interactions médicamenteuses)

Other Cardiovascular Agents Enalaprilat injection, USP has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. (notice Énalaprilate, Interactions médicamenteuses)

…PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (notice Finastéride, Interactions médicamenteuses)

Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (notice Fingolimod, Interactions médicamenteuses)

Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). (notice Mémantine, Interactions médicamenteuses)

Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). (notice Mémantine et donépézil, Interactions médicamenteuses)

Cross-Allergy Cross-allergy may occur when metolazone tablets, USP, are given to patients known to be allergic to sulfonamide-derived drugs, thiazides, or quinethazone. (notice Métolazone, Mises en garde)

Drug Interactions Bacteriostatic antibacterials ( i.e. , chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. (notice Pénicilline G, Interactions médicamenteuses)

Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (notice Pentoxifylline, Interactions médicamenteuses)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (notice Perphénazine, Interactions médicamenteuses)

There is a potential cross-sensitivity between silver sulfadiazine and other sulfonamides. (notice Sulfadiazine argentique, Mises en garde et précautions)

Angiotensin Receptor Blockers, Angiotensin Converting Enzyme Inhibitors and Potassium Sparing Diuretics Although specific interaction studies were not performed, in clinical studies, tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. (notice Tolvaptan, Interactions médicamenteuses)

Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (notice Ibutilide, Interactions médicamenteuses)